Minnesota · 2025-2026 Regular Session · Bill
HF 4349: Provisions governing hospital reimbursement for biological products to treat rare diseases modified.
In committee Official data
- Introduced
- In committee
- Passed one chamber
- Passed both chambers
- Enacted
Last official action: ·Record last updated:
Plain-language summary
HF 4349 is a bill introduced in the Minnesota House on March 16, 2026. According to its official title, it concerns: Provisions governing hospital reimbursement for biological products to treat rare diseases modified. Primary sponsor: Robert Bierman (Democratic-Farmer-Labor). It lists 4 additional sponsors. Most recent recorded action (March 16, 2026): Introduction and first reading, referred to Health Finance and Policy.
Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written
Sponsors
Sponsors by party (alphabetical): Democratic-Farmer-Labor 5
| Name | Role | Party | Chamber | District |
|---|---|---|---|---|
| Robert Bierman | Primary sponsor | Democratic-Farmer-Labor | House | 56A |
| Kristin Bahner | Co-sponsor | Democratic-Farmer-Labor | House | 37B |
| John Huot | Co-sponsor | Democratic-Farmer-Labor | House | 56B |
| Anquam Mahamoud | Co-sponsor | Democratic-Farmer-Labor | House | 62B |
| Liz Reyer | Co-sponsor | Democratic-Farmer-Labor | House | 52A |
“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.
Recent official actions
- Introduction and first reading, referred to Health Finance and Policy